Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study (TaISENWITCH)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01679964 |
Recruitment Status
:
Completed
First Posted
: September 6, 2012
Last Update Posted
: September 15, 2016
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infection Adverse Drug Reaction Quality of Life | Drug: Raltegravir switch | Phase 4 |
A. Objectives To compare the treatment-emerged AEs and virological suppression after switch to raltegravir-based therapy in stable HIV-infected patients who receiving ritonavir-boosted protease inhibitor antiretroviral regimen
Primary endpoints:
1) The changes in overall incidence and severity of patient-reported clinical adverse events (based on "symptom distress module) after switch to raltegravir-based therapy.
Secondary endpoints:
- The proportion of patients who are free of "virological failure" at week 48 after switch
- The change from baseline in CD4 cell counts at week 48 after switch
- The change in quality of life by assess the changes in the domain scores of MOS-HIV questionnaire at baseline and different study time points.
- The changes in laboratory adverse event, e.g., the mean percent changes from baseline to 48 weeks in plasma lipid profile (total cholesterol, LDLCholesterol, HDL Cholesterol, triglycerides) after switch
- The proportion of patients who are free of "treatment failure" at week 48 after switch
Safety endpoints
- Incidence of adverse events
- The proportion of patients with treatment-related grade 3 or 4 adverse events and laboratory abnormalities
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 107 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Single Arm Study to Assess the Sustained Virological Suppression and Improvement of Treatment-emerged Adverse Events of Switching to Raltegravir in Stable HIV-infected Patients on Ritonavir-boosted Protease Inhibitor Regimen |
Study Start Date : | July 2012 |
Actual Primary Completion Date : | February 2015 |
Actual Study Completion Date : | February 2015 |

Arm | Intervention/treatment |
---|---|
Raltegravir switch
Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
|
Drug: Raltegravir switch
Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
Other Name: Isentress
|
- The proportion of patient-reported clinical adverse events [ Time Frame: Week 4, 12-16, 28-32, 48 ]The proportion of patient-reported clinical adverse events in total and by severity (based on symptom distress module) at 4 weeks, The proportion of patient-reported clinical adverse events in total and by severity (based on symptom distress module) at 12-16 weeks, The proportion of patient-reported clinical adverse events in total and by severity (based on symptom distress module) at 28-32 weeks, The proportion of patient-reported clinical adverse events in total and by severity (based on symptom distress module) at 48 weeks
- The proportion of patients who are free of "virological failure" [ Time Frame: Week 4, 12-16, 28-32, 48 ]The proportion of patients who are free of "virological failure" at week 4 after switch, The proportion of patients who are free of "virological failure" at week 12-16 after switch, The proportion of patients who are free of "virological failure" at week 28-32 after switch, The proportion of patients who are free of "virological failure" at week 48 after switch
- The change from baseline in CD4 cell counts [ Time Frame: Week 4, 12-16, 28-32, 48 ]The change from baseline in CD4 cell counts at week 4 after switch, The change from baseline in CD4 cell counts at week 12-16 after switch, The change from baseline in CD4 cell counts at week 28-32 after switch, The change from baseline in CD4 cell counts at week 48 after switch
- the change from baseline in life quality (based on the MOS-HIV questionnaire) [ Time Frame: week 12-16, 48 ]The change from baseline in quality of life (based on the MOS-HIV questionnaire) at week 12-16 after switch, The change from baseline in quality of life (based on the MOS-HIV questionnaire) at week 48 after switch.
- The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) [ Time Frame: Week 4, 12-16, 28-32, 48 ]The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 4 weeks, The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 12-16 weeks, The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 28-32 weeks, The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 48 weeks
- The proportion of patients with treatment failure [ Time Frame: Week 4, 12-16, 28-32, 48 ]The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 4 weeks, The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 12-16 weeks, The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 28-32 weeks, The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 48 weeks

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients who are infected with HIV-1
- Ages at least 20 years
- Patients are currently receiving a ritonavir-boosted PI-based regimen, including lopinavir, atazanavir, or darunavir, plus at least 2 antiretroviral agents (NRTIs)
- Patient complained of treatment-emerged clinical adverse events or abnormal lipid profile
- Patients with plasma HIV-1 viral RNA below 50 copies per ml for at least 6 months
Exclusion Criteria:
- Patient with known history of contraindication or hypersensitivity to any component of the study regimen
- Patients with acute or decompensated chronic hepatitis in the previous 6 months
- Patients with chronic hepatitis and serum aminotransferase concentrations are more than 5 times the upper limit of the normal range
- Patients with renal insufficiency (patients need dialysis or have serum creatinine concentrations of more than twice the upper limit of the normal range
- Current alcohol or substance abuse (patients receiving methadone for the management of withdrawal symptoms due to substance abuse are allowed )
- Patients have failed previous regimens (prior to starting the current 2NRTI+PI/r regimen they are currently on)
- Patient's viral load have not been consistently <50 copies per ml for 6 months or longer.
- Patients initiated lipid lowering agents during the preceding 3 months
- Patients with any medical disorder or history of any illness which, in the opinion of the investigator, that the use of study medications is contraindicated or might confound the results of the study or pose additional risk in administering study drugs to the patient
- Pregnant, wish to become pregnant during the study period or breastfeeding women
- Patients who are lack of expectation to maintain assigned study medication during study period
- Patients who have received therapy with investigational drugs in the previous 3 months

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01679964
Taiwan | |
Kaohsiung Medical University Chung-Ho Memorial Hospital | |
Kaohsiung, Taiwan, 807 | |
E-Da Hospital | |
Kaohsiung, Taiwan, 824 | |
China Medical University Hospital | |
Taichung, Taiwan, 40447 | |
National Cheng Kung University Hospital | |
Tainan, Taiwan, 704 | |
National Taiwan University Hospital | |
Taipei, Taiwan, 10048 | |
Taipei City Hospital | |
Taipei, Taiwan, 108 | |
Chang Gung Memorial Hospital at Linkou | |
Taoyuan, Taiwan, 333 |
Principal Investigator: | Hsi-Hsun Lin, MD | E-DA Hospital |
Publications:
Responsible Party: | Lin, Hsi-Hsun, M.D. |
ClinicalTrials.gov Identifier: | NCT01679964 History of Changes |
Other Study ID Numbers: |
MISP40301 MISP 40301 ( Other Grant/Funding Number: MISP 40301 ) |
First Posted: | September 6, 2012 Key Record Dates |
Last Update Posted: | September 15, 2016 |
Last Verified: | September 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Keywords provided by Lin, Hsi-Hsun, M.D.:
HIV infection Raltegravir Adverse event Life quality |
Additional relevant MeSH terms:
HIV Infections Drug-Related Side Effects and Adverse Reactions Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Chemically-Induced Disorders Raltegravir Potassium |
Protease Inhibitors HIV Protease Inhibitors Reverse Transcriptase Inhibitors Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents HIV Integrase Inhibitors Integrase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Nucleic Acid Synthesis Inhibitors |